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Splicing variants are less commonly reported than other
variant types [1–3]. However, despite most being func-
tional nulls, previous reports suggested that they are
under-recognized [2]. Our recent experience of investi-
gating a cohort of 38 individuals with a severe, genetically
heterogeneous Mendelian phenotype shows that this
continues to be a problem; three variants that affected
splicing were initially “missed” because they were not
detected by current splice site detection algorithms. Our
concern is that splicing variants will continue to be
overlooked in clinical laboratory settings because the
quantity of data generated per person by “exomes” and
“genomes” necessitates the use of splice site detection
programs. Our cases highlight signiﬁcant deﬁciencies in
current standard programs, where variants at the U2
canonical AG (acceptor) and GT (donor) splice sites are
reliably detected, but variants at other positions with more
loosely deﬁned consensus sequences, or U12 splice sites,
are rarely detected [4].
We analyzed 38 sequentially ascertained samples
from individuals who were born unable to feel pain
within an UK NHS genetic service. We initially found
28 of the 38 cases had bi-allelic variants that affected
function in SCN9A (17), NTRK1 (13) and NGF (1);
all causing autosomal recessive painless disorders.
Given the speciﬁc phenotype and limited genotypes, we
hand-curated the remaining cases. In three unrelated
index individuals rare variants within intronic regions
were present on sequencing (ExAC frequencies of
2/113990, 0/61864, and 2/120742). Splice site prediction
program analysis of each variant was performed using
Alamut (http://www.interactive-biosoftware.com/alamut-
visual/), which incorporates ﬁve different programs all
of which have been developed for U2 splice sites rather than
U12 splice sites (see Table 1). Whilst the three variants
were not ﬂagged, we considered they could alter splice site
function due to their proximity to known splice sites, and
assessed each by a minigene splicing assay [5], as tran-
scriptomic sequencing was not possible (see Supplement for
methodology).
Each variant was proven to alter splicing by comparing
the results to those of normal wild-type splicing (see Fig. 1).
The ﬁrst case had a hereditary sensory and
autonomic neuropathy type 4 (HSAN4) phenotype but
sequencing analysis had detected no variants, however
we noted a homozygous NTRK1 variant, c.575–19 G >A
(reference sequence NM_002529.3; exons are numbered
as in the reference sequence NG_007493.1) [6]. Bioinfor-
matics analysis suggested that this potentially created a
new AG splice acceptor site, which was predicted to be
superior to the existing site; this was the case, with
the introduction of a 17 bp frame-shifting insertion into
the NTRK1 mRNA (Fig. 1b.ii). The second case also
had a HSAN4 phenotype but sequencing had revealed
only one NTRK1 heterozygous variant proven to affect
function c.1550 G > A6. On sequence inspection we noted a
heterozygous splice donor site variant c.717+ 4 A > T.
Although usually+ 4 can be any base, in NTRK1 this+ 4
position is invariant [7]. The minigene assay showed
that the variant resulted in complete loss of NTRK1 exon 6
in the mature transcript (Fig. 1b.iii). The third case had a
phenotype consistent with congenital insensitivity to pain
(CIP)—a lack of pain and smell perception with
normal intelligence. Only a single heterozygous variant in
SCN9A was detected, c.2686 C > T (reference sequence
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NM_002977.3; exons are numbered as in the reference
sequence NG_012798.1). On inspection of the sequencing
data we noted a heterozygous variant c.377+ 5 C > T
in SCN9A occurring in a U12 splice site. The U12 donor
site sequence is RTATCCTT where +5 C is invariant [8],
in contrast to the more ubiquitous U2 splice site where +5
can vary [7]. The variant caused complete loss of exon 3
and aberrant splicing into a cryptic U2 acceptor site
resulting in a +1 frame shift (Fig. 1c.ii). All three variants
were predicted to lead to nonsense-mediated decay
and hence be nulls. Early nonsense and frame shift variants
have been identiﬁed in other cases of HSAN4 and
CIP patients and hence are likely to explain the disease
in our patients [9].
In our cohort, a tenth of cases harbored missed variants
that affected splicing. Their detection was considerably
aided by the clear phenotype and the limited number of
genes that required analysis. Had the phenotype been more
variable, or did not resemble a single-gene disorder, or the
number of potentially causative genes greater, it is possible
that these variants would have gone undetected. These cases
also illustrate the need to consider seeking a second variant
in autosomal recessive phenotypes when only a hetero-
zygous variant is found; generally the chance of there being
a second variant is greater than the chance the person is an
incidental carrier.
As the volume of genetic data generated per person
continues to increase (from exon-by-exon analysis,
through gene panels, to exomes, and now whole genome
sequencing), this has inevitably led to a greater reliance
on variant detection programs. The limitations of these
algorithms to detect splicing variants, especially those
occurring in U12 introns and less well deﬁned consensus
sequences, needs to be better recognized and urgently
remedied (for instance, by the use of the Spliceman pro-
gram, see Table. 1), otherwise, the full potential of genetic
testing will be limited [10]. Until then, researchers in
clinical laboratories should be vigilant in seeking splicing
variants and perhaps should hand-curate for rare varia-
tions occurring beyond −1, −2, +1, +2 sites. If splicing
variants that affect function are missed by splicing pre-
diction programs, or by a conservatism to prevent the
identiﬁcation of too many variants of unclear signiﬁcance
in clinical laboratories, then this has two important con-
sequences. Firstly, it decreases the utility of exome/gen-
ome scale sequencing, and secondly, it increases the risk
that other variations may be erroneously regarded as
disease-causing.
Table 1 Summary of the results
of splice prediction programs for
detecting the wild-type splice
sites, and the effects of variants
on each
Was the variant predicted to alter
the splice site by
NTRK1 c.575–19 G > A
Exon 6 acceptor site
NTRK1 c.717+ 4 A
> T Exon 6 donor
site
SCN9A c.377+ 5 C
> T Exon 3 donor
site
MaxEntScan (1–16) Yes: 5 to 3.7 Yes: 7.2 to 1.7 No: ND
SpliceSiteFinder-like (0–100) No: 75 to 75 No: 81 to 71 No: ND
Human Splicing Finder (0–100) No: 82.5 to 82.5 No: 91 to 82 No: ND
GeneSplicer (0–15) No: 2.5 to 2.5 Yes: 9.2 to 2.5 No: ND
NNSplice (0–1) No: 0.9 to 0.9 Yes: 0.7 to 0 No: ND
Spliceman (0–100) Yes: 75 Yes: 55 Yes: 82
The Alamut program, which incorporates MaxEntScan, SpliceSiteFinder-like, Human Splicing Finder,
GeneSplicer and NNSplice, was used as the primary assessment tool for the intronic variants. For each
prediction program in Alamut we have indicated the scale range in brackets and have stated whether the
variants were predicted to be deleterious in bold if the change in variation was greater than 15% (yes/no) and
given the score of the wild-type splice site and the effect of the variant below the prediction. At least three of
the ﬁve programs had to strongly predict an effect on splicing at the canonical splice site in order to be
considered as disease-causing by the clinical laboratory.
The NTRK1 c.575–19 G > A variant was only predicted to have deleterious effects on the wildtype acceptor
site by one program, MaxEntScan. The NTRK1 c.717+ 4 A > T variant had deleterious predictions in three
programs but as the +4 position was known to be the least conserved it was not ﬂagged as being likely to
affect function. The SCN9A exon 3 splice site was not detected as a splice site by any of the ﬁve programs in
Alamut, and hence the effect of the variant could not be determined. This was unsurprising as the intron 3 of
SCN9A is a U12 intron, for which none of the Alamut programs were designed. However, the more recently
written splice prediction program Spliceman did predicted the splice site and the deleterious effect of the
variant. Spliceman reports variants as a percentage; the higher the percentile rank, the more likely it is the
variation will disrupt splicing.
ND: wildtype splice was not detected by the program
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Fig. 1 Summary of minigene assay and sequencing results demonstrating the functional consequences of three “missed” splicing variants. The
USR13-v1 vector, used for minigene assays, (a) contains COL2A1 exons 43–46 and intervening introns. Between exon 44 and 45, a multiple
cloning site is present to allow cloning of the test region. NTRK1 exon 6 and ﬂanking intronic regions were introduced into the vector. SCN9A exon
3, intron 3–4 and exon 4, as well as ﬂanking intronic regions were introduced into the vector. Exons are shown as colored boxes; blue and green for
the minigene exons (exon 44 and 45 of COL2A1), orange for NTRK1 exon 6, and grey and purple for SCN9A exons 3 and 4. Mini-gene constructs
of wild-type and mutant NTRK1 exon 6 (b) and SCN9A exon 3 and 4 (c), with their ﬂanking intronic regions, were expressed in HeLa cells. PCR
was performed on cDNA converted from extracted mRNA and sequenced. For each reaction the left panel is a schematic of the splicing event and
the right panel an annotated chromatogram of sequence from the minigene PCR reaction. The splice acceptor and donor site nucleotides are shown
surrounding the exons studied, with the invariant nucleotides enlarged. The variants investigated are shown in red. Black arrows indicate normal
splicing. For each variant, a loss of a black arrow indicated that splicing at that site failed to occur, and red arrows indicate new splice sites formed
because of the variants. b.i details the normal splicing of NTRK1 exon 6. b.ii shows the effect of c.575–19 G >A producing a novel splice acceptor
site 19 bp from the start of exon 6 - resulting in the addition of 17 nucleotides into the mRNA, a frameshift and a premature stop codon. b.iii shows
the effect of c.717+ 4 A > T, a splice donor variant at +4 bp: the whole of exon 6 is missing from the ﬁnal transcript resulting in a frame-shift in
the reading frame of the mRNA and a premature stop codon. c.i details the normal splicing event for SCN9A exon 3 and 4, where intron 3 has
U12 splicing. c.ii shows the effect of c.377+ 5 C > T in the +5 site in the U12 donor site sequence of SCN9A intron 3. This lead to a complete
failure of splicing of exon 3, and the use of a cryptic U2 splice donor site prior to the U12 splice acceptor site of exon 4 resulting in 4 bp of intron 3
being added to exon 4. This resulted in a+ 1 frame shift, a stop codon at the 21st codon of exon 4, and nonsense-mediated decay
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